Volume 12, Number 8—August 2006
Research
Antibody Response to Pneumocystis jirovecii
Table 2
Antibody levels to major surface glycoprotein C in Pneumocystis pneumonia patients by CD4+ count and week of observation*
Week | All patients |
CD4+ <50 cells/μL |
CD4+ >50 cells/μL |
|||
---|---|---|---|---|---|---|
n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | n | Geometric mean (95% CI) | |
Baseline (0) | 80 | 4.2 (3.1–5.8) | 54 | 4.2 (2.8–6.3) | 26 | 4.4 (2.5–7.6) |
1–2 | 25 | 8.0 (4.1–15.8) | 17 | 7.3 (3.0–17.8) | 8 | 9.9 (2.8–35.3) |
3–4 | 19 | 10.4 (4.7–23.1)† | 13 | 6.3 (2.4–16.4) | 6 | 30.4 (7.1–129.5)‡ |
5–6 | 18 | 3.7 (2.0–6.8) | 10 | 5.5 (2.0–15.0) | 8 | 2.3 (1.2–4.4) |
*n = no. patients who were observed at the specified follow-up time and at baseline. CI, confidence interval.
†p<0.001 vs. week 0, p<0.001 vs. weeks 1–2, and p<0.001 vs. weeks 5–6.
‡p<0.001 vs. week 0, p<0.001 vs. weeks 5–6, p<0.03 vs. weeks 3–4 in CD4+ <50 cells/μL group.